Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals
Frontiers in Pharmacology · 07.03.2023 · 14
DOI: 10.3389/fphar.2023.1126714 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 07.03.2023. Verfasst von Guoliang Deng und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Biology and Biological Engineering, South China University of Technology, Guangzhou, Guangdong, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Chronic kidney disease (CKD) has significant effects on renal clearance of drugs. The application of antibiotics in CKD patients to achieve the desired therapeutic effect is challenging. This study aims to determine meropenem plasma exposure in the CKD population and further investigate optimal dosing regimens.
Methods
A healthy adult PBPK model was established using the meropenem’s physicochemical parameters, pharmacokinetic parameters, and available clinical data, and it was scaled to the populations with CKD and dialysis. The differences between the predicted concentration, C max , and AUC last predicted and observed model values were assessed by mean relative deviations (MRD) and geometric mean fold errors (GMFE) values and plotting the goodness of fit plot to evaluate the model’s performance. Finally, dose recommendations for CKD and hemodialysis populations were performed by Monte Carlo simulations.
Results
The PBPK models of meropenem in healthy, CKD, and hemodialysis populations were successfully established. The MRD values of the predicted concentration and the GMFE values of C max and AUC last were within 0.5–2.0-fold of the observed data. The simulation results of the PBPK model showed the increase in meropenem exposure with declining kidney function in CKD populations. The dosing regimen of meropenem needs to be further adjusted according to the renal function of CKD patients. In patients receiving hemodialysis, since meropenem declined more rapidly during the on-dialysis session than the off-dialysis session, pharmacodynamic evaluations were performed for two periods separately, and respective optimal dosing regimens were determined.
Conclusion
The established PBPK model successfully predicted meropenem pharmacokinetics in patients with CKD and hemodialysis and could further be used to optimize dosing recommendations, providing a reference for personalized clinical medication.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Biology and Biological Engineering, South China University of Technology, Guangzhou, Guangdong, China.
- Department of Pharmacy, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
- Department of Hepatobiliary Surgery, Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China.
- Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
Zitieren
APA
Deng, G., Yang, F., Sun, N., Liang, D., Cen, A., Zhang, C., & Ni, S. (2023). Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1126714
Vancouver
Deng G, Yang F, Sun N, Liang D, Cen A, Zhang C, et al. Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1126714
BibTeX
@article{Deng2023,
author = {Deng, Guoliang and Yang, Fan and Sun, Ning and Liang, Danhong and Cen, Anfen and Zhang, Chen and Ni, Suiqin},
title = {Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1126714}
}
EUVIMED